TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent.

Telix, a biopharmaceutical company, announces that its prostate cancer PET imaging agent Illuccix (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization ...

Dozens of people gathered in St. Albans on Thursday to see the unveiling of the new microchip scanning station at the St.

The S&P/ASX 200 Index (ASX: XJO) healthcare stock is charging higher again on Friday following another FDA goal.

Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh is one of the country’s hubs for researchers ...

FDG-PET imaging is not routinely employed in this type of cancer and its role in endometrial cancer is still being studied and yet to be defined. In a series of 41 whole-body PET studies conducted ...